Lisa Cook sues Trump over firing attempt, emergency hearing set
Investing.com -- SKAN Group (SIX:SKAN)p on Tuesday reported record results in 2024, with a 21.8% surge in order intake to CHF 359.5 million and a 12.9% increase in net sales to CHF 361.3 million.
The Swiss company’s EBITDA rose by 13.6% to CHF 57 million, maintaining a margin of 15.8%.
According to SKAN, the demand was driven by "the ongoing trend towards injectable drugs, and thus towards our process solutions for the aseptic filling of biopharmaceutical active ingredients, ensuring high demand among our customers."
The Equipment & Solutions segment remained SKAN’s primary revenue driver, contributing 75% of total sales.
The segment recorded an EBITDA increase of 12.9% to CHF 30.3 million, with a margin of 11.2%. Meanwhile, the Services & Consumables segment saw an order intake increase of 27.6%, pushing net sales to CHF 90.4 million.
This segment’s EBITDA grew by 14.4% to CHF 26.6 million, with a strong margin of 29.5%.
In Asia, order intake more than doubled to CHF 48.1 million, bringing its share to 13.4% from 6.4%.
Europe remained the largest market, with order intake reaching CHF 207 million, an increase of 17.6%. The Americas posted a modest increase to CHF 97.9 million, up 3.2%.
SKAN’s net profit surged by 46.2% to CHF 40.8 million, reflecting strong operational performance.
The company’s equity increased by 14.9% to CHF 202.6 million, while operating cash flow saw a jump from CHF 8.7 million in 2023 to CHF 46.7 million in 2024, highlighting improved cash generation and financial stability.
Investments for the year totaled CHF 53.8 million, with a focus on infrastructure expansion in Switzerland, Germany, and Belgium, as well as an increased stake in Aseptic Technologies S.A.
The establishment of SKAN do Brasil Ltda. marked an important milestone in its international growth strategy.
SKAN expects mid-teens percentage sales growth in 2025, with an EBITDA margin target of 14-16%.
The company acknowledged potential short-term project execution delays but expressed confidence in its ability to recover, stating, "From today’s perspective, the Board of Directors and Management expect a subdued sales development in the first half of 2025. However, we assume that the resulting shortfall in sales and earnings can be largely compensated for in the second half of the year."
The Board of Directors has proposed a dividend of CHF 0.40 per share for 2024, reflecting a 14.3% increase, while earnings per share climbed 47.5% to CHF 1.73.
SKAN’s workforce grew by 83 employees to 1,471, representing a 6% increase, with total headcount, including temporary staff, reaching 1,654.